Memsift Innovations bags $1.62 mn order from global pharma major
The Hindu
Memsift Innovations wins $1.62M contract to revolutionise industrial liquid waste treatment. Pilot program unveiled in 2022, resulting in 90% cost savings, 80% reduction in carbon footprint & 490 tons of CO2 emissions cut annually. Commercial implementation to start in 2024.
Singapore-based Memsift Innovations has bagged a $1.62-million commercial contract from a leading Fortune 100 pharmaceutical company to revolutionise industrial liquid waste treatment and zero liquid discharge solutions.
The global pharma giant initiated a technical feasibility study in 2019. The study aimed to assess the feasibility of utilising TS-30 Improved Membrane Distillation system to treat liquid waste resulted in reducing liquid waste volume by more than 90% while recovering high-quality nitrogen fertiliser, the waste-to-value added product company said in a statement.
Building on the positive outcomes of the feasibility study, a full-scale onsite pilot program was unveiled in early 2022 and has been in continuous operation for over a year.
“This bold move will not only enable the pharma major to achieve more than 90% cost savings in waste disposal but also reduce its carbon footprint by up to 80% compared to conventional disposal and incineration methods, resulting in an estimated reduction of 490 tons of CO2 emissions annually,” said Memsift Innovations Pte. Ltd.’s Founder & CEO J. Antony Prince.
The commercial implementation of this project is slated to begin in the first quarter of 2024.
Air India has signed an agreement with Bengaluru Airport City Limited (BACL), a subsidiary of Bangalore International Airport Limited (BIAL), to develop a built-to-suit facility for the AME program that will feature modern classrooms, well-equipped laboratories for practical training and a team of qualified trainers.